Table 2.
Demographic and clinical features of OS and nOS patients
| Gender | Onset | DD | UPDRS | HY | Subtype | Side* | DA | LD | DA LEDD | Total§ LEDD | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OS patients | |||||||||||
| M | 60 | 12 | 18 | 2 | AR | L | Rop | 600 | 160 | 760 | |
| M | 63 | 3 | 20 | 1 | TR | L | Pra | - | 112 | 112 | |
| M | 64 | 6 | 28 | 3 | TR | R | - | 300 | - | 300 | |
| M | 53 | 17 | 25 | 2.5 | TR | R | Pra | 400 | 150 | 550 | |
| M | 47 | 10 | 22 | 2 | TR | L | Rop | 800 | 160 | 1060 | |
| F | 65 | 5 | 10 | 2 | TR | L | Rop | - | 120 | 120 | |
| M | 64 | 14 | 37 | 2.5 | TR | R | Pra | 300 | 150 | 450 | |
| F | 46 | 16 | 26 | 2 | TR | R | Pra | 750 | 200 | 950 | |
| M | 68 | 5 | 18 | 2 | TR | L | Rot | 600 | 120 | 820 | |
| M | 70 | 5 | 35 | 2.5 | AR | L | - | 400 | - | 400 | |
| M | 53 | 21 | 53 | 4 | TR | R | Pra | 800 | 300 | 1200 | |
| nOS patients | |||||||||||
| M | 62 | 7 | 10 | 1 | TR | L | Pra | 200 | 0.75 | 375 | |
| M | 72 | 5 | 14 | 2 | TR | L | Rop | 420 | 50 | 470 | |
| M | 61 | 11 | 30 | 2 | TR | R | Pra | 600 | 150 | 750 | |
| M | 50 | 12 | 22 | 2 | AR | L | Pra | 450 | 300 | 750 | |
| M | 49 | 9 | 30 | 2.5 | TR | L | Pra | 400 | 75 | 475 | |
| F | 62 | 9 | 25 | 2.5 | TR | L | - | 500 | - | 500 | |
| F | 45 | 16 | 8 | 1.5 | TR | R | Pra | 300 | 300 | 600 | |
| M | 60 | 12 | 26 | 2.5 | AR | L | Rot | 700 | 120 | 820 | |
| M | 66 | 7 | 25 | 2 | TR | L | Rop | 100 | 120 | 320 | |
| M | 63 | 2 | 24 | 1 | TR | R | Pra | - | 300 | 300 | |
| M | 51 | 21 | 44 | 4 | AR | R | Pra | 1400 | 300 | 1700 | |
Abbreviations: OS Othello syndrome; DD disease duration; UPDRS Unified Parkinson’s Disease Rating Scale section III: HY Hoehn and Yahr scale; DA dopaminergic agonists; LD levodopa (mg); LEDD levodopa dose equivalence (mg); AR akinetic-rigid form; TR tremulous form; L left; R right; Rop ropinirole; Pra pramipexole; Rot rotigotine
*More affected side
§Total LEDD also includes other anti-PD drugs (MAO-B and COMT inhibitors, amantadine, and anticholinergics)